Apexigen, Inc. - Common Stock APGN 深 滬
已收盤 08-23 16:00:00 美东时间
0.3851
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.3851
- 總市值 957.43万
- 52周最高 8.28
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.3305
- 委 比 0.00%
- 總股本 2486.19万
- 歷史最高 31.35
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.3305
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多89bio names Francis Sarena as COO
89bio (NASDAQ:ETNB) said it has appointed Francis Sarena as COO, effective August 5. Sarena has over two decades of experience, and served as COO and president at Apexigen before joining ETNB. More on...
2024-08-07 20:25
Pyxis Oncology gets $8M payment for sale pf royalty rights
Pyxis Oncology (NASDAQ:PYXS) said it has completed the sale of its rights to royalties from the commercialization of Beovu and another asset to Novartis for a one-time cash payment of $8 million. The ...
2024-03-27 19:43
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, CPRI, APGN
NEW YORK, Aug. 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
2023-08-12 02:59
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers HeartBeam (NASDAQ:BEAT) stock rose 20.1% to $2.42 during Thursday's pr...
2023-05-25 21:07
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNL, RTL, APGN
NEW YORK, May 24, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...
2023-05-25 00:37
Pyxis Oncology Bolsters Oncology Portfolio Through $16M Apexigen Acquisition
Pyxis Oncology (NASDAQ:PYXS) has announced an acquisition of Apexigen (NASDAQ:APGN) that is expected to be completed in the second half of 2023.
2023-05-25 00:19
Apexigen shares are trading higher after Pyxis Oncology announced it will acquire the company.
Apexigen shares are trading higher after Pyxis Oncology announced it will acqui...
2023-05-24 20:35
Pyxis Oncology to Acquire Apexigen
Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) develop...
2023-05-24 18:45
EF Hutton Maintains Buy on Apexigen, Lowers Price Target to $5
EF Hutton analyst Tony Butler maintains Apexigen (NASDAQ:APGN) with a Buy and lowers the price target from $8 to $5.
2023-05-16 19:12
Apexigen（纳斯达克股票代码：APGN）交易价格上涨3.5％
Apexigen, Inc. (NASDAQ:APGN – Get Rating) traded up 3.5% during trading on Wedn...
2023-04-06 15:22
